GB953626A
(en)
|
1961-04-25 |
1964-03-25 |
Meito Sangyo Kk |
Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
|
US4525339A
(en)
|
1982-10-15 |
1985-06-25 |
Hoffmann-La Roche Inc. |
Enteric coated oral dosage form
|
AU581177B2
(en)
|
1983-05-31 |
1989-02-16 |
Choong-Gook Jang |
Dry direct compression compositions for controlled release dosage forms
|
DE3331009A1
(de)
|
1983-08-27 |
1985-03-14 |
Basf Ag, 6700 Ludwigshafen |
Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
|
US4590062A
(en)
|
1984-04-16 |
1986-05-20 |
Tech Trade Corp. |
Dry direct compression compositions for controlled release dosage forms
|
US4654155A
(en)
|
1985-03-29 |
1987-03-31 |
Reynolds Metals Company |
Microemulsion lubricant
|
US5288497A
(en)
|
1985-05-01 |
1994-02-22 |
The University Of Utah |
Compositions of oral dissolvable medicaments
|
US4764375A
(en)
|
1985-09-11 |
1988-08-16 |
Kv Pharmaceutical Company |
Sachet drug delivery system
|
US4789547A
(en)
|
1987-06-17 |
1988-12-06 |
Warner-Lambert Company |
Transdermal matrix system
|
IL87710A
(en)
|
1987-09-18 |
1992-06-21 |
Ciba Geigy Ag |
Covered floating retard form for controlled release in gastric juice
|
US5221734A
(en)
|
1987-10-01 |
1993-06-22 |
Ciba-Geigy Corporation |
Process for preparing a polypeptide growth factor for milk
|
GB2212396A
(en)
|
1987-12-18 |
1989-07-26 |
Procter & Gamble |
Dietary supplement comprising calcium and delayed release coated iron
|
NO179479C
(no)
|
1988-03-11 |
1996-10-16 |
Teikoku Seiyaku Kk |
Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
|
US5169933A
(en)
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5190748A
(en)
|
1988-11-22 |
1993-03-02 |
Hoffmann-La Roche Inc. |
Absorption enhancement of antibiotics
|
ZA898331B
(en)
|
1988-11-22 |
1990-07-25 |
Hoffmann La Roche |
Pharmaceutical compositions
|
IL92537A
(en)
|
1988-12-15 |
1994-04-12 |
Riker Laboratories Inc |
Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
|
GB2244015B
(en)
|
1990-03-14 |
1993-10-27 |
Hadley Sections Limited |
Tube and method of forming same
|
US5541155A
(en)
|
1994-04-22 |
1996-07-30 |
Emisphere Technologies, Inc. |
Acids and acid salts and their use in delivery systems
|
US5110606A
(en)
|
1990-11-13 |
1992-05-05 |
Affinity Biotech, Inc. |
Non-aqueous microemulsions for drug delivery
|
IT1245761B
(it)
|
1991-01-30 |
1994-10-14 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
|
US5744450A
(en)
|
1991-03-14 |
1998-04-28 |
The Salk Institute For Biological Studies |
GnRH analogs
|
US5688761A
(en)
|
1991-04-19 |
1997-11-18 |
Lds Technologies, Inc. |
Convertible microemulsion formulations
|
JPH06507172A
(ja)
|
1991-04-19 |
1994-08-11 |
アフィニティー バイオテック,インコーポレイテッド |
転換可能なミクロエマルジョン処方剤
|
AU653026B2
(en)
|
1991-06-07 |
1994-09-15 |
Teikoku Seiyaku Kabushiki Kaisha |
Physiologically active polypeptide-containing pharmaceutical composition
|
SK279589B6
(sk)
|
1991-11-22 |
1999-01-11 |
Procter And Gamble Pharmaceuticals |
Farmaceutický prípravok s retardovaným uvoľňovaním
|
US5229130A
(en)
|
1991-12-20 |
1993-07-20 |
Cygnus Therapeutics Systems |
Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
|
SE501389C2
(sv)
|
1992-04-24 |
1995-01-30 |
Leiras Oy |
Farmaceutiskt preparat och förfarande för dess framställning
|
DE4317458A1
(de)
|
1992-06-11 |
1993-12-16 |
Bayer Ag |
Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
|
JP3190441B2
(ja)
|
1992-07-20 |
2001-07-23 |
エーザイ株式会社 |
塩酸アゼラスチンを含有する安定な製剤
|
RU2068689C1
(ru)
|
1992-09-24 |
1996-11-10 |
Товарищество с ограниченной ответственностью "Лекрон" |
Способ получения таблеток парацетамола
|
ES2176209T3
(es)
|
1992-11-06 |
2002-12-01 |
Hisamitsu Pharmaceutical Co |
Preparacion farmaceutica oral liberable en el tracto digestivo inferior.
|
US5346701A
(en)
|
1993-02-22 |
1994-09-13 |
Theratech, Inc. |
Transmucosal delivery of macromolecular drugs
|
SE9302135D0
(sv)
|
1993-06-18 |
1993-06-18 |
Kabi Pharmacia Ab |
New pharmaceutical composition
|
TW402506B
(en)
|
1993-06-24 |
2000-08-21 |
Astra Ab |
Therapeutic preparation for inhalation
|
ES2068762B1
(es)
|
1993-07-21 |
1995-12-01 |
Lipotec Sa |
Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
|
US5707648A
(en)
|
1993-11-17 |
1998-01-13 |
Lds Technologies, Inc. |
Transparent liquid for encapsulated drug delivery
|
DE69530973T2
(de)
|
1994-02-16 |
2004-05-19 |
Abbott Laboratories, Abbott Park |
Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
|
US5506207A
(en)
|
1994-03-18 |
1996-04-09 |
The Salk Institute For Biological Studies |
GNRH antagonists XIII
|
US5639469A
(en)
|
1994-06-15 |
1997-06-17 |
Minnesota Mining And Manufacturing Company |
Transmucosal delivery system
|
IL110024A
(en)
|
1994-06-15 |
1998-04-05 |
Yissum Res Dev Co |
Controlled release oral drug delivery system containing hydrogel- forming polymer
|
GB9414318D0
(en)
|
1994-07-15 |
1994-09-07 |
Dowelanco Ltd |
Preparation of aqueous emulsions
|
AU713461B2
(en)
|
1994-11-17 |
1999-12-02 |
Toray Industries, Inc. |
Preparation for percutaneous absorption
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
KR19990014865A
(ko)
|
1995-05-17 |
1999-02-25 |
피터 이. 브래이브맨 |
소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
US6572879B1
(en)
|
1995-06-07 |
2003-06-03 |
Alza Corporation |
Formulations for transdermal delivery of pergolide
|
GB9516268D0
(en)
|
1995-08-08 |
1995-10-11 |
Danbiosyst Uk |
Compositiion for enhanced uptake of polar drugs from the colon
|
US5626884A
(en)
*
|
1995-08-18 |
1997-05-06 |
Lockett; Curtis G. |
Treatment of sickle cell disease
|
US5766620A
(en)
|
1995-10-23 |
1998-06-16 |
Theratech, Inc. |
Buccal delivery of glucagon-like insulinotropic peptides
|
US5807983A
(en)
|
1995-12-28 |
1998-09-15 |
The Salk Institute For Biological Studies |
GNRH antagonist betides
|
JP2000511532A
(ja)
|
1996-05-20 |
2000-09-05 |
メルク エンド カンパニー インコーポレーテッド |
性腺刺激ホルモン放出ホルモンのアンタゴニスト
|
US6150522A
(en)
|
1996-05-20 |
2000-11-21 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US6147088A
(en)
|
1996-05-20 |
2000-11-14 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US5916582A
(en)
|
1996-07-03 |
1999-06-29 |
Alza Corporation |
Aqueous formulations of peptides
|
US5932547A
(en)
|
1996-07-03 |
1999-08-03 |
Alza Corporation |
Non-aqueous polar aprotic peptide formulations
|
GB9614235D0
(en)
|
1996-07-06 |
1996-09-04 |
Danbiosyst Uk |
Composition for enhanced uptake of polar drugs from mucosal surfaces
|
US5952000A
(en)
|
1996-10-30 |
1999-09-14 |
Theratech, Inc. |
Fatty acid esters of lactic acid salts as permeation enhancers
|
US5925730A
(en)
|
1997-04-11 |
1999-07-20 |
Ferring Bv |
GnRH antagonists
|
US5821230A
(en)
|
1997-04-11 |
1998-10-13 |
Ferring Bv |
GnRH antagonist decapeptides
|
US6156772A
(en)
|
1997-06-05 |
2000-12-05 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US6004984A
(en)
|
1997-06-05 |
1999-12-21 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US6156767A
(en)
|
1997-06-05 |
2000-12-05 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US5981550A
(en)
|
1997-06-05 |
1999-11-09 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
IL121268A0
(en)
|
1997-07-09 |
1998-01-04 |
Dpharm Ltd |
Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
|
IL121269A0
(en)
|
1997-07-09 |
1998-01-04 |
Dpharm Ltd |
Compositions and methods for reversibly increasing permeability of biomembranes
|
SE9703691D0
(sv)
|
1997-10-10 |
1997-10-10 |
Astra Ab |
Pharmaceutical compositions
|
US6017944A
(en)
|
1997-10-28 |
2000-01-25 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
ATE246506T1
(de)
|
1998-03-11 |
2003-08-15 |
Grelan Pharmaceutical Co |
Darmlösliche sprudelnde zusammensetzungen
|
US6077847A
(en)
|
1998-04-02 |
2000-06-20 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US6025366A
(en)
|
1998-04-02 |
2000-02-15 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US5998432A
(en)
|
1998-04-02 |
1999-12-07 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
US6270804B1
(en)
|
1998-04-03 |
2001-08-07 |
Biovail Technologies Ltd. |
Sachet formulations
|
GB2336311A
(en)
|
1998-04-15 |
1999-10-20 |
Merck & Co Inc |
Bisphosphonate Dosing Regimen
|
US6656922B2
(en)
|
1998-05-28 |
2003-12-02 |
Mediplex Corporation, Korea |
Oral delivery of macromolecules
|
JP3853985B2
(ja)
*
|
1998-08-03 |
2006-12-06 |
有限会社 健康百二十才 |
鉄イオン含有殺菌液
|
AU1071200A
(en)
|
1998-10-19 |
2000-05-08 |
Biotech Australia Pty Limited |
Systems for oral delivery
|
US8119159B2
(en)
|
1999-02-22 |
2012-02-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
EP1154761B1
(en)
*
|
1999-02-22 |
2008-02-20 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
SE9901272D0
(sv)
|
1999-04-09 |
1999-04-09 |
Astra Ab |
New improved formulation
|
JP2001081031A
(ja)
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
EP1438966B1
(en)
|
1999-12-08 |
2007-02-14 |
Cyclacel Pharmaceuticals, Inc. |
Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
|
IL142515A0
(en)
|
1999-12-20 |
2002-03-10 |
Merck & Co Inc |
Pharmaceutical kit
|
US20020002140A1
(en)
|
2000-01-14 |
2002-01-03 |
Holick Michael F. |
Novel bisphosphonates and uses thereof
|
JP2004517800A
(ja)
|
2000-04-07 |
2004-06-17 |
ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム |
両性イオンリン脂質およびビスホスホネートを含む独特の組成物および胃腸毒性を低減化したビスホスフェートデリバリーシステムとしての該組成物の使用
|
US6468559B1
(en)
|
2000-04-28 |
2002-10-22 |
Lipocine, Inc. |
Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
|
IT1318539B1
(it)
|
2000-05-26 |
2003-08-27 |
Italfarmaco Spa |
Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
|
CN1141974C
(zh)
|
2000-06-07 |
2004-03-17 |
张昊 |
结肠定位释放的口服生物制剂
|
EP1296689B3
(en)
|
2000-06-20 |
2013-02-13 |
Novartis AG |
Method of administering bisphosphonates
|
WO2002055017A2
(en)
|
2000-11-21 |
2002-07-18 |
Wake Forest University |
Method of treating autoimmune diseases
|
GB0029111D0
(en)
|
2000-11-29 |
2001-01-10 |
Novartis Ag |
Organic compounds
|
US6379960B1
(en)
|
2000-12-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of damage-specific DNA binding protein 2, p48 expression
|
US20020103131A1
(en)
|
2001-01-26 |
2002-08-01 |
Jacobson Jill D. |
Prevention of diabetes by administration of GnRH antagonists
|
JP2004525110A
(ja)
|
2001-02-16 |
2004-08-19 |
清水製薬株式会社 |
ムコ多糖類製剤およびその製造法
|
KR20030083725A
(ko)
|
2001-03-01 |
2003-10-30 |
에미스페어 테크놀로지스, 인코포레이티드 |
비스포스포네이트 전달용 조성물
|
MXPA03010007A
(es)
|
2001-05-02 |
2004-02-12 |
Novartis Ag |
USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
|
CA2446622C
(en)
|
2001-05-11 |
2012-08-14 |
Elan Corporation, Plc |
Isostearic acid salts as permeation enhancers
|
CA2452056C
(en)
|
2001-07-02 |
2011-11-01 |
Elan Corporation, Plc. |
Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
|
US20030031757A1
(en)
*
|
2001-08-03 |
2003-02-13 |
Kraft Food Holdings, Inc. |
Stable and bioavailable iron fortified beverages
|
US7098305B2
(en)
|
2001-09-06 |
2006-08-29 |
Ardana Bioscience Limited |
Sustained release of microcrystalline peptide suspensions
|
DE10157628A1
(de)
|
2001-11-26 |
2003-06-12 |
Zentaris Ag |
Injektionslösung eines LHRH-Antagonisten
|
US7214662B2
(en)
|
2001-11-27 |
2007-05-08 |
Zentaris Gmbh |
Injectable solution of an LHRH antagonist
|
AU2002362039B2
(en)
|
2001-12-03 |
2007-07-26 |
Soligenix, Inc |
Stabilized reverse micelle compositions and uses thereof
|
JP2005516928A
(ja)
|
2001-12-13 |
2005-06-09 |
メルク エンド カムパニー インコーポレーテッド |
骨異常のためのビスホスホネート液体製剤
|
KR20040066177A
(ko)
|
2001-12-19 |
2004-07-23 |
알자 코포레이션 |
친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
|
US7351800B2
(en)
|
2002-02-28 |
2008-04-01 |
Nipro Corporation |
Stabilized albumin preparations
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
MXPA04009586A
(es)
|
2002-05-10 |
2005-01-11 |
Hoffmann La Roche |
Acidos bisfosfonicos para el tratamiento y prevencion de la osteoporosis.
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2005020913A2
(en)
|
2003-08-25 |
2005-03-10 |
Combinatorx, Incorporated |
Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
|
MXPA06003063A
(es)
|
2003-09-19 |
2006-05-31 |
Pfizer Prod Inc |
Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
|
JP2007509974A
(ja)
*
|
2003-10-31 |
2007-04-19 |
アルザ・コーポレーシヨン |
3−アミノプロピル−n−ブチルホスフィン酸の増大した吸収のための組成物および薬用量形態
|
US8987322B2
(en)
|
2003-11-04 |
2015-03-24 |
Circ Pharma Research And Development Limited |
Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
|
DE10358525A1
(de)
|
2003-12-13 |
2005-07-07 |
Bayer Healthcare Ag |
Endoparasitizide Mittel zur topischen Applikation
|
AR046773A1
(es)
|
2003-12-23 |
2005-12-21 |
Novartis Ag |
Formulaciones farmaceuticas de bisfosfonatos
|
WO2005062041A1
(en)
|
2003-12-24 |
2005-07-07 |
Astrazeneca Ab |
Pharmaceutical dissolution testing using a non-ionic surfactant
|
US7606313B2
(en)
|
2004-01-15 |
2009-10-20 |
Ittiam Systems (P) Ltd. |
System, method, and apparatus for error concealment in coded video signals
|
WO2005072747A1
(ja)
|
2004-02-02 |
2005-08-11 |
Ono Pharmaceutical Co., Ltd. |
骨吸収抑制剤
|
US8241670B2
(en)
|
2004-04-15 |
2012-08-14 |
Chiasma Inc. |
Compositions capable of facilitating penetration across a biological barrier
|
US20070219131A1
(en)
|
2004-04-15 |
2007-09-20 |
Ben-Sasson Shmuel A |
Compositions capable of facilitating penetration across a biological barrier
|
US20070212395A1
(en)
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
ES2349584T3
(es)
|
2004-05-24 |
2011-01-05 |
Warner Chilcott Company, Llc |
Forma de dosificación sólida entérica para administración oral de un bifosfonato que contiene un agente quelante.
|
WO2006010155A2
(en)
|
2004-07-16 |
2006-01-26 |
Oakwood Laboratories, L.L.C |
Gonadotropin releasing hormone antagonists
|
CN101027318B
(zh)
|
2004-07-19 |
2016-05-25 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
WO2006024631A2
(en)
|
2004-08-31 |
2006-03-09 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
EP1674082A1
(de)
|
2004-12-22 |
2006-06-28 |
Zentaris GmbH |
Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
|
CN101198316A
(zh)
|
2005-03-17 |
2008-06-11 |
伊兰制药国际有限公司 |
纳米微粒双膦酸盐组合物
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
IL174387A0
(en)
|
2005-03-31 |
2008-01-20 |
Dexcel Pharma Technologies Ltd |
A solid composition for intra-oral delivery of insulin
|
US8968781B2
(en)
*
|
2005-04-29 |
2015-03-03 |
Cubist Pharmaceuticals, Inc. |
Therapeutic compositions
|
WO2006125762A1
(en)
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Stabilized polypeptide formulations
|
JP2009501700A
(ja)
|
2005-06-17 |
2009-01-22 |
ダイナミス・セラピユーテイクス・インコーポレーテツド |
炎症状態の治療
|
MX2008000974A
(es)
|
2005-07-22 |
2008-03-27 |
Univ California |
Composiciones de heparina e inhibicion de selectina.
|
US20070077313A1
(en)
*
|
2005-10-04 |
2007-04-05 |
U.S. Pharmaceutical Corporation |
Toleration iron supplement compositions
|
US7704977B2
(en)
|
2006-04-07 |
2010-04-27 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
CN101125132A
(zh)
|
2007-07-25 |
2008-02-20 |
司炳奎 |
口服胰岛素肠溶胶囊及其制备方法
|
WO2009137078A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of peptides and processes of preparation thereof
|
SI2343982T1
(sl)
|
2008-09-17 |
2017-08-31 |
Chiasma Inc. |
Farmacevtski sestavki in metode povezane z dostavo
|
US20100215743A1
(en)
|
2009-02-25 |
2010-08-26 |
Leonard Thomas W |
Composition and drug delivery of bisphosphonates
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
EP2651395A4
(en)
|
2010-12-15 |
2014-05-07 |
Merrion Res Iii Ltd |
PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION
|